Moa Life Plus

Moa Life Plus EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Moa Life Plus (142760.KQ) as of Oct 30, 2026 is -6.53 B KRW. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -7.34 B KRW — a change of -11.07% (higher).

EBITDA

-6.53 BKRW

YoY

-11.07%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Moa Life Plus is 2025 -6.53 B KRW. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Moa Life Plus was 2024 -7.34 B KRW. It decreases by -11.07% higher compared to the previous year.

The Moa Life Plus EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-11.26 B KRW
Jan 1, 2019
-37.24 B KRW
Jan 1, 2020
-32.14 B KRW
Jan 1, 2021
-34.74 B KRW
Jan 1, 2022
-13.85 B KRW
Jan 1, 2023
-4.99 B KRW
Jan 1, 2024
-7.34 B KRW
Jan 1, 2025
-6.53 B KRW
The Moa Life Plus EBITDA history
YEAREBITDAYoY
-6.53 BKRW-11.07%
-7.34 BKRW+47.23%
-4.99 BKRW-63.98%
-13.85 BKRW-60.14%
-34.74 BKRW+8.10%
-32.14 BKRW-13.68%
-37.24 BKRW+230.56%
-11.26 BKRW+62.07%
-6.95 BKRW+24.14%
-5.60 BKRW+5.81%
-5.29 BKRW+77.81%
-2.98 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Moa Life Plus Stock analysis

What does Moa Life Plus do? BL Corp. develops biopharmaceutical products and manufactures health functional foods and functional cosmetics. The company distributes Glu 100 Tablets, CellribonQ, and GentaQ to general hospitals and pharmacies. It generates revenue through the sale of these pharmaceuticals and health-related products to healthcare providers and retail outlets. The firm's product portfolio includes Glu 100 Tablets, CellribonQ, and GentaQ, which are distributed to general hospitals and pharmacies. These products are sold as part of the company's pharmaceutical and medical supplies distribution business. Revenue is derived from the sale of these branded medicines and health functional products. BL Corp. focuses on the distribution of specific branded pharmaceuticals and health functional products. The company's primary customers are general hospitals and pharmacies, which purchase Glu 100 Tablets, CellribonQ, and GentaQ for resale or direct use in healthcare settings. Moa Life Plus is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Moa Life Plus stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Moa Life Plus is -6.53 B KRW in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Moa Life Plus changed from -7.34 B KRW to -6.53 B KRW, representing a -11.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Moa Life Plus since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Moa Life Plus historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Moa Life Plus

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Moa Life Plus